[Effectiveness of passive immunisation against respiratory syncytium virus in a group of premature infants with birth weight below 1000 grams].
Respiratory syncytial virus (RSV) is a major cause of respiratory tract infection during the child's first year of life. Those who survive neonatal intensive care are commonly rehospitalized. In the absence of vaccine, passive immunoprophylaxis is the preferred approach. Safety and efficacy of Palivizumab (Synagis) was proven in the Impact-RSV Trial, conducted in the USA, Canada and UK. The aim of the study was to determine efficacy of humanized monoclonal RSV antibody in prematures infants born 25-32 week gestation with weight birth below 1000 g with and without broncho-pulmonary dysplasia. We compared the hospitalization rates and morbidity between two groups of children who received palivizumab and without any protection. We confirm the efficacy and safety of Synagis. The outcome of this study supports the use of palivizumab prophylaxis in high-risk children.
Korbal
Piotr
P
Regionalnego Ośrodka Opieki Perinatalnej AM w Bydgoszczy.
Mikołajczak
Aleksandra
A
Szymański
Wiesław
W
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007116:Immunization, Passive / Q000379:methods; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D019102:Infant, Very Low Birth Weight; D007363:Intensive Care Units, Neonatal / Q000706:statistics & numerical data; D008297:Male; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000276:immunology* / Q000517:prevention & control; D012136:Respiratory Syncytial Viruses / Q000187:drug effects* / Q000276:immunology; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab